Literature DB >> 21694818

Management of vestibular migraine.

Alexandre R Bisdorff1.   

Abstract

Vestibular migraine is considered to be the second most common cause of vertigo and the most common cause of spontaneous episodic vertigo. The duration of attacks varies from seconds to days, usually lasting minutes to hours, and they mostly occur independently of headaches. Long-lasting individual attacks are treated with generic antivertiginous and antiemetic drugs. Specific antimigraine drugs are unlikely to be very effective for rescue. The mainstay of the management of vestibular migraine is prophylactic medication. To date, there are no controlled trials available; the body of knowledge builds on case series and retrospective or observational studies. Most drugs are also used for the prevention of migraine headaches. The choice of medication should be guided by its side effect profile and the comorbidities of patients. Betablockers such as propanolol or metoprolol are preferred in patients with hypertension but in the absence of asthma. Anticonvulsants include topiramate when patients are obese, valproic acid and lamotrigine. Lamotrigine is preferred if vertigo is more frequent than headaches. Calcium antagonists include verapamil and flunarizine. If patients have anxiety, tricyclic antidepressants such as amitryptiline or nortryptiline or SSRIs and benzodiazepines such as clonazepam are recommended. Acetazolamide is effective in rare genetic disorders related to migraine-like episodic ataxia; however, its place in vestibular migraine is still to be established. Nonpharmacological measures such as diet, sleep, hygiene and avoidance of triggers are recommended as they are for migraine. Vestibular rehabilitation might be useful when there are complications such as loss of confidence in balance or visual dependence.

Entities:  

Keywords:  anti-convulsants; beta-blockers; migraine; prophylaxis; vestibular

Year:  2011        PMID: 21694818      PMCID: PMC3105632          DOI: 10.1177/1756285611401647

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  77 in total

1.  Acetazolamide treatment for migraine aura status.

Authors:  J Haan; P Sluis; L H Sluis; M D Ferrari
Journal:  Neurology       Date:  2000-11-28       Impact factor: 9.910

2.  Episodic vertigo related to migraine (90 cases): vestibular migraine?

Authors:  M Dieterich; T Brandt
Journal:  J Neurol       Date:  1999-10       Impact factor: 4.849

3.  Psychiatric comorbidity in different organic vertigo syndromes.

Authors:  Annegret Eckhardt-Henn; Christoph Best; Sandra Bense; Peter Breuer; Gudrun Diener; Regine Tschan; Marianne Dieterich
Journal:  J Neurol       Date:  2008-03-14       Impact factor: 4.849

4.  The interrelations of migraine, vertigo, and migrainous vertigo.

Authors:  H Neuhauser; M Leopold; M von Brevern; G Arnold; T Lempert
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

Review 5.  The cerebellum and migraine.

Authors:  Maurice Vincent; Nouchine Hadjikhani
Journal:  Headache       Date:  2007-06       Impact factor: 5.887

6.  Vestibular rehabilitation outcomes in patients with a history of migraine.

Authors:  Diane M Wrisley; Susan L Whitney; Joseph M Furman
Journal:  Otol Neurotol       Date:  2002-07       Impact factor: 2.311

7.  Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo.

Authors:  Roberto Albera; Roberto Ciuffolotti; Maurizio Di Cicco; Giuseppe De Benedittis; Irene Grazioli; Gabriella Melzi; Eugenio Mira; Eugenio Pallestrini; Desiderio Passali; Agostino Serra; Claudio Vicini
Journal:  Acta Otolaryngol       Date:  2003-06       Impact factor: 1.494

8.  Clinical spectrum of episodic ataxia type 2.

Authors:  J Jen; G W Kim; R W Baloh
Journal:  Neurology       Date:  2004-01-13       Impact factor: 9.910

Review 9.  Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

10.  Prevalence of vertigo, dizziness, and migrainous vertigo in patients with migraine.

Authors:  Vlasta Vuković; Davor Plavec; Ivana Galinović; Arijana Lovrencić-Huzjan; Mislav Budisić; Vida Demarin
Journal:  Headache       Date:  2007 Nov-Dec       Impact factor: 5.887

View more
  28 in total

1.  Detecting Signals of Disproportionate Reporting from Singapore's Spontaneous Adverse Event Reporting System: An Application of the Sequential Probability Ratio Test.

Authors:  Cheng Leng Chan; Sowmya Rudrappa; Pei San Ang; Shu Chuen Li; Stephen J W Evans
Journal:  Drug Saf       Date:  2017-08       Impact factor: 5.606

2.  Management of mal de debarquement syndrome as vestibular migraines.

Authors:  Yaser Ghavami; Yarah M Haidar; Kasra N Ziai; Omid Moshtaghi; Jay Bhatt; Harrison W Lin; Hamid R Djalilian
Journal:  Laryngoscope       Date:  2016-10-12       Impact factor: 3.325

3.  Fixed combination of cinnarizine and dimenhydrinate in the prophylactic therapy of vestibular migraine: an observational study.

Authors:  R Teggi; B Colombo; O Gatti; G Comi; M Bussi
Journal:  Neurol Sci       Date:  2015-06-03       Impact factor: 3.307

Review 4.  Migraine and vertigo.

Authors:  Arun Swaminathan; Jonathan H Smith
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

5.  Outcome of vestibular rehabilitation in vestibular migraine.

Authors:  Birgul Balci; Gülden Akdal
Journal:  J Neurol       Date:  2022-07-08       Impact factor: 4.849

6.  A novel locus for episodic ataxia:UBR4 the likely candidate.

Authors:  Judith Conroy; Paul McGettigan; Raymond Murphy; David Webb; Sinéad M Murphy; Blathnaid McCoy; Christine Albertyn; Dara McCreary; Cara McDonagh; Orla Walsh; Sallyann Lynch; Sean Ennis
Journal:  Eur J Hum Genet       Date:  2013-08-28       Impact factor: 4.246

7.  Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial.

Authors:  Anjali Lepcha; Sophia Amalanathan; Ann Mary Augustine; Amit Kumar Tyagi; Achamma Balraj
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-29       Impact factor: 2.503

Review 8.  Optimal management of Ménière's disease.

Authors:  Carol A Foster
Journal:  Ther Clin Risk Manag       Date:  2015-02-25       Impact factor: 2.423

Review 9.  Epilepsy and the cortical vestibular system: tales of dizziness and recent concepts.

Authors:  Russell Hewett; Fabrice Bartolomei
Journal:  Front Integr Neurosci       Date:  2013-11-11

10.  Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions.

Authors:  Stefan Unterecker; Andreas Reif; Susanne Hempel; Florian Proft; Peter Riederer; Jürgen Deckert; Bruno Pfuhlmann
Journal:  Int Clin Psychopharmacol       Date:  2014-07       Impact factor: 1.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.